Dynavax Technologies Corporation (NASDAQ:DVAX) Receives $24.33 Average Price Target from Analysts

Dynavax Technologies Corporation (NASDAQ:DVAX) has received an average recommendation of “Hold” from the five brokerages that are covering the stock, Marketbeat Ratings reports. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and two have given a buy rating to the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $24.3333.

DVAX has been the topic of several recent research reports. Wall Street Zen upgraded shares of Dynavax Technologies from a “buy” rating to a “strong-buy” rating in a research note on Saturday, December 27th. William Blair cut Dynavax Technologies from an “outperform” rating to a “hold” rating in a research report on Wednesday, December 24th. Finally, Weiss Ratings restated a “sell (d)” rating on shares of Dynavax Technologies in a research note on Wednesday, October 8th.

Insiders Place Their Bets

In other Dynavax Technologies news, COO David F. Novack sold 30,000 shares of the company’s stock in a transaction on Wednesday, December 24th. The shares were sold at an average price of $15.49, for a total transaction of $464,700.00. Following the sale, the chief operating officer directly owned 111,451 shares of the company’s stock, valued at approximately $1,726,375.99. This represents a 21.21% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders own 2.98% of the company’s stock.

Institutional Investors Weigh In On Dynavax Technologies

Several hedge funds have recently bought and sold shares of the company. Profund Advisors LLC increased its position in Dynavax Technologies by 2.7% during the third quarter. Profund Advisors LLC now owns 38,380 shares of the biopharmaceutical company’s stock worth $381,000 after buying an additional 995 shares during the last quarter. Parkman Healthcare Partners LLC raised its stake in Dynavax Technologies by 0.4% in the 3rd quarter. Parkman Healthcare Partners LLC now owns 271,306 shares of the biopharmaceutical company’s stock valued at $2,694,000 after acquiring an additional 1,175 shares during the period. Osaic Holdings Inc. lifted its holdings in Dynavax Technologies by 15.1% during the 2nd quarter. Osaic Holdings Inc. now owns 9,336 shares of the biopharmaceutical company’s stock valued at $93,000 after purchasing an additional 1,226 shares during the last quarter. Rafferty Asset Management LLC boosted its position in Dynavax Technologies by 0.9% during the third quarter. Rafferty Asset Management LLC now owns 164,206 shares of the biopharmaceutical company’s stock worth $1,631,000 after purchasing an additional 1,516 shares during the period. Finally, Jacobs Levy Equity Management Inc. increased its holdings in shares of Dynavax Technologies by 1.4% in the third quarter. Jacobs Levy Equity Management Inc. now owns 118,484 shares of the biopharmaceutical company’s stock valued at $1,177,000 after purchasing an additional 1,610 shares during the last quarter. 96.96% of the stock is currently owned by institutional investors and hedge funds.

Dynavax Technologies Stock Up 0.3%

NASDAQ:DVAX opened at $15.72 on Friday. The stock has a 50-day simple moving average of $12.34 and a 200 day simple moving average of $11.04. Dynavax Technologies has a 52-week low of $9.20 and a 52-week high of $15.73. The company has a market cap of $1.85 billion, a PE ratio of -42.49 and a beta of 0.89. The company has a debt-to-equity ratio of 0.41, a quick ratio of 6.94 and a current ratio of 7.62.

Dynavax Technologies (NASDAQ:DVAX) last released its quarterly earnings results on Wednesday, November 5th. The biopharmaceutical company reported $0.21 earnings per share for the quarter, topping analysts’ consensus estimates of $0.14 by $0.07. The firm had revenue of $94.88 million during the quarter, compared to the consensus estimate of $94.00 million. Dynavax Technologies had a positive return on equity of 7.18% and a negative net margin of 13.13%. On average, sell-side analysts expect that Dynavax Technologies will post 0.32 EPS for the current fiscal year.

About Dynavax Technologies

Dynavax Technologies Corporation is a biopharmaceutical company focused on the development and commercialization of novel vaccines and immunotherapies. Headquartered in Emeryville, California, the company specializes in leveraging its proprietary Toll-like receptor (TLR) agonist platform to enhance immune responses. Its lead product, HEPLISAV-B, is a two-dose hepatitis B vaccine approved by the U.S. Food and Drug Administration that incorporates the CpG 1018 adjuvant to stimulate a rapid and robust antibody response in adults.

Founded in 1993, Dynavax has built a pipeline that extends beyond hepatitis B to include candidates targeting seasonal influenza, respiratory syncytial virus (RSV) and emerging infectious diseases.